$1437.84
10.560.74%
Dern. MÀJ: Nov 13, 10:38 AM
Eli Lilly and rose 39.7% from $1,021.37 to $1,427.28, ahead of the S&P 500's +12.7%. Its worst day was Feb 5 (−7.8%), and its low came Apr 29 at $851.21.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $7.54 beat the $6.96 estimate on $19.3B revenue (est. $17.9B); FY revenue guidance of $80.0B–$83.0B against the $77.5B consensus.
+10.3%, the year's best day · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
HSBC moved Eli Lilly and from Hold to Reduce and cut its price target from $1,070.00 to $850.00; shares fell 5.9%.
−5.9% · S&P 500 +0.3%
EPS of $8.55 beat the $6.85 estimate on $19.8B revenue (est. $17.8B); FY revenue guidance of $82.0B–$85.0B against the $81.9B consensus.
+9.8%, on 8M shares, the year's heaviest volume · S&P 500 +1.0%
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The Journal of Clinical
+7.1% · S&P 500 −0.7%
EPS of $8.38 beat the $6.01 estimate on $23.0B revenue (est. $20.4B); FY revenue guidance of $85.0B–$87.0B against the $85.4B consensus.
+4.9% · S&P 500 −0.2%
EPS of $7.48 beat the $6.36 estimate on $24.4B revenue (est. $22.5B); FY revenue guidance of $91.0B–$92.0B against the $88.8B consensus.
+6.6% · S&P 500 −0.4%
Where it ended: a close of $1427.28 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 3, 2027 (EPS est. $11.14, revenue est. $24.7B).
As of the Nov 12, 2026 close
Replay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LLY and SPY from Benzinga historical bars. Not investment advice.